Gilead wins US FDA OK of second triple combo HIV pill
This article was originally published in Scrip
Antiviral powerhouse Gilead Sciences won the US FDA's blessing on its latest once-daily HIV medicine Complera, which combines into a single tablet its long-time marketed fixed-dose combination nucleoside reverse transcriptase inhibitor Truvada (emtricitabine and tenofovir disoproxil fumarate) with Tibotec Pharmaceuticals' non-nucleoside reverse transcriptase inhibitor (NNRTI) Edurant (rilpivirine), which was approved in the US in May (scripintelligence, 23 May 2011).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.